KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) EPS (Basic): 2018-2025

Historic EPS (Basic) for Castle Biosciences (CSTL) over the last 8 years, with Sep 2025 value amounting to -$0.02.

  • Castle Biosciences' EPS (Basic) fell 125.00% to -$0.02 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.41, marking a year-over-year decrease of 286.36%. This contributed to the annual value of $0.66 for FY2024, which is 130.84% up from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' EPS (Basic) is -$0.02, which was down 112.50% from $0.16 recorded in Q2 2025.
  • Over the past 5 years, Castle Biosciences' EPS (Basic) peaked at $0.35 during Q4 2024, and registered a low of -$1.10 during Q1 2023.
  • In the last 3 years, Castle Biosciences' EPS (Basic) had a median value of -$0.09 in 2024 and averaged -$0.20.
  • Its EPS (Basic) has fluctuated over the past 5 years, first slumped by 1,066.67% in 2023, then spiked by 488.89% in 2024.
  • Quarterly analysis of 5 years shows Castle Biosciences' EPS (Basic) stood at -$0.25 in 2021, then slumped by 216.00% to -$0.79 in 2022, then skyrocketed by 88.61% to -$0.09 in 2023, then surged by 488.89% to $0.35 in 2024, then tumbled by 125.00% to -$0.02 in 2025.
  • Its EPS (Basic) was -$0.02 in Q3 2025, compared to $0.16 in Q2 2025 and -$0.90 in Q1 2025.